Rachel Collins, MD, MBA
Hospital ResidentCards
About
Research
Publications
2025
A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy
Goodman R, Burnette H, Johnson D. A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy. 2025, 449-454. DOI: 10.1007/978-3-031-83533-9_56.Peer-Reviewed Original ResearchCharacterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
Fletcher K, Goodman R, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely J, Yeoh H, Rapisuwon S, Haydon A, Osman I, Mehnert J, Long G, Sullivan R, Carlino M, Menzies A, Dewan A, Johnson D. Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors. JAMA Dermatology 2025, 161: 555-557. PMID: 40072456, PMCID: PMC11904794, DOI: 10.1001/jamadermatol.2025.0025.Peer-Reviewed Original ResearchSafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchUrban versus non-urban patient geographic status impacts melanoma survival: a surveillance, epidemiology, and end results (SEER) database study
Thakker S, Belzberg M, Gulati N, Goodman R, Gulati N. Urban versus non-urban patient geographic status impacts melanoma survival: a surveillance, epidemiology, and end results (SEER) database study. Archives Of Dermatological Research 2025, 317: 494. PMID: 40009240, DOI: 10.1007/s00403-025-04015-2.Commentaries, Editorials and Letters
2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank C, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson D, Mcarthur G, Rutkowski P, Neyns B, Sullivan R, Weber J, Carlino M, Ascierto P, Lo S, Long G, Menzies A. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. European Journal Of Cancer 2024, 212: 115055. PMID: 39366209, DOI: 10.1016/j.ejca.2024.115055.Peer-Reviewed Original ResearchPrimary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study
Goodman R, Jung S, Fletcher K, Burnette H, Mohyuddin I, Irlmeier R, Ye F, Johnson D. Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study. Cancers 2024, 16: 2355. PMID: 39001417, PMCID: PMC11240575, DOI: 10.3390/cancers16132355.Peer-Reviewed Original Research
2023
Accuracy and Reliability of Chatbot Responses to Physician Questions
Goodman R, Patrinely J, Stone C, Zimmerman E, Donald R, Chang S, Berkowitz S, Finn A, Jahangir E, Scoville E, Reese T, Friedman D, Bastarache J, van der Heijden Y, Wright J, Ye F, Carter N, Alexander M, Choe J, Chastain C, Zic J, Horst S, Turker I, Agarwal R, Osmundson E, Idrees K, Kiernan C, Padmanabhan C, Bailey C, Schlegel C, Chambless L, Gibson M, Osterman T, Wheless L, Johnson D. Accuracy and Reliability of Chatbot Responses to Physician Questions. JAMA Network Open 2023, 6: e2336483. PMID: 37782499, PMCID: PMC10546234, DOI: 10.1001/jamanetworkopen.2023.36483.Peer-Reviewed Original ResearchLong-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Goodman R, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long G, Sullivan R, Carlino M, Atkinson V, Trojanello C, Ascierto P, Schadendorf D, Warburton L, Menzies A, Santinami M, Johnson D. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal Of Cancer 2023, 194: 113354. PMID: 37827067, PMCID: PMC10843257, DOI: 10.1016/j.ejca.2023.113354.Peer-Reviewed Original ResearchPublic Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative Review
Goodman R, Mittal L, Parker E. Public Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative Review. JMIR Dermatology 2023, 6: e48998. PMID: 37676716, PMCID: PMC10514763, DOI: 10.2196/48998.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDelayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma
Goodman R, Justice J, Gardner L, Singh R, Dewan A, Johnson D. Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma. European Journal Of Cancer 2023, 192: 113255. PMID: 37595488, PMCID: PMC10900129, DOI: 10.1016/j.ejca.2023.113255.Commentaries, Editorials and Letters